Bristol-Myers Squibb Company (BMY) Stock Analysis
Bristol-Myers Squibb Company by the reported numbers
On the most recently reported figures, Bristol-Myers Squibb Company (BMY) shows revenue down 0.2% and earnings per share up 178% year over year.
The business runs a net margin of 14.6%, a free cash flow margin of 26.7% and a 30.1% return on equity.
The ImpliedLens normalized earnings-value model places the shares 130% above the current price under its disclosed assumptions, which you can change. At today's price the market is implying 40.0% less growth than the reported figures support.
Valuation
| Forward P/E | 13.9× | Price / trailing four-quarter actual EPS · Sep 30, 2026 |
|---|---|---|
| Model upside | +130% | ImpliedLens normalized earnings-value model · Oct 29, 2026 |
| Conservative case | +13.8% | ImpliedLens conservative earnings-value model · Oct 29, 2026 |
| Implied growth gap | −40.0% | ImpliedLens price-expectations model · Oct 29, 2026 |
Growth
| Revenue growth | −0.2% | SEC filing · Oct 29, 2026 |
|---|---|---|
| EPS growth | +178% | SEC filing · Oct 29, 2026 |
| Share count change | +0.4% | SEC filing · Oct 29, 2026 |
Profitability and returns
| Net margin | 14.6% | Derived from SEC filing · Oct 29, 2026 |
|---|---|---|
| Free cash flow margin | 26.7% | SEC filing · Oct 29, 2026 |
| Return on equity | 30.1% | Derived from SEC filing · Oct 29, 2026 |
Balance sheet
| Equity / assets | 26.4% | Derived from SEC filing · Oct 29, 2026 |
|---|
Every figure above carries the source it came from and the date it was reported. Company filings as of Oct 29, 2026. Figures are reported and derived data, not advice, and the valuation model is one set of assumptions you can change.